Please help

Amy Dyken, controller at Whispering Pharmaceutical Industries a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Whispering's financial statements. Below is selected financial information for. 1. Options were granted on July 1,2024 , to purchase 190,000 shares at $16 per share. Although no options were exercised during fiscal year 2025 , the average price per common share during fiscal year 2025 was $20 per share. 2. Each bond was issued at face value. The 9% comvertible bonds will convert into common stock at 50 shares per $1,000 bond. The bonds are exercisable after 5 years and were issued in fiscal year 2024. 3. The preferred stock was issued in 2024. 4. There are no preferred dividends in arrears; however, preferred dividends were not declared in fiscal year 2025. 5. The 990,000 shares of common stock were outstanding for the entire 2025 fiscal year. 6. Net income for fiscal year 2025 was $1,520,000, and the average income tax rate is 20%. For the fiscal year ended June 30,2025, calculate the following for Whispering Pharmaceutical Industries. (Round answers to 2 decimal ploces,eg. 2.45.) 3. Basic eamings per share. Basicearnings per share b. Diluted earnings per share. Diluted earnings per share s